Pancreatic cancer is feeling the heat.
adenocarcinoma
combination therapy
gastrointestinal cancer
immunotherapy
tumor microenvironment - TME
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
accepted:
12
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Pancreatic adenocarcinoma (PDAC) is considered an immunologically 'cold' tumor that fails to attract or support effector T cells. Most PDACs are resistant to immune checkpoint blockade due to the complex signaling pathways that exist within its tumor microenvironment. Recent advances in genomic and proteomic technology advances are finally uncovering the complex inflammatory cellular and intercellular signals that require modulation and reprogramming. The goal is to 'turn up the heat' on PDACs with combination immunotherapies that incorporate T cell activating agents and immune modulatory agents, and successfully eradicate tumors. Here, we discuss progress and promising new research that is moving the field toward this goal.
Identifiants
pubmed: 39467640
pii: jitc-2024-010124
doi: 10.1136/jitc-2024-010124
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: EMJ reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, CPRIT, Surge Tx, Mestag, Medical Home Group, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. EMJ is the Dana and Albert 'Cubby' Broccoli Professor of Oncology.